This Market Spotlight report covers the Zika Virus market, comprising key pipeline therapies, clinical trials, probability of success, and epidemiology.
Key Takeaways
- A total of 89 countries and territories have had documented evidence of autochthonous mosquito-borne transmission of Zika virus, including five of the six WHO regions, as of December 2021.
- The majority of industry-sponsored drugs in active clinical development for Zika virus are in Phase I, with a single product in Phase II.
- Therapies in development for Zika virus focus on the immune system, viral antigens, and RNA polymerase. Candidates comprise DNA vaccines such as GeneOne’s GLS-5700 and Inovio’s INO-A002; Moderna’s mRNA vaccine; Imutex’s AGS-v and AGS-v PLUS vaccines; Takeda’s TAK-426 vaccine; Emergent BioSolutions’ ZIKV-IG vaccine; and BioCryst’s galidesivir, a broad-spectrum antiviral drug.
- The overall likelihood of approval of a Phase I antiviral asset is 12.6%, and the average probability a drug advances from Phase III is 65.3%. Drugs, on average, take 8.4 years from Phase I to approval, compared to 8.9 years in the overall infectious disease space.
- All clinical trials for Zika virus have been in either Phase I or Phase II, with no Phase III trials to date.
- The US leads in terms of the number of Zika virus clinical trials globally.
- Inovio, GeneOne, Moderna, Emergent BioSolutions, and Merck & Co have two completed trials each in the Zika virus space. • Inovio, Moderna, and Sanofi lead industry sponsors with three clinical trials each for Zika virus.
CONTENTS
5 OVERVIEW
6 KEY TAKEAWAYS
7 DISEASE BACKGROUND
8 TREATMENT
8 Vaccines
8 Therapeutics
10 EPIDEMIOLOGY
11 PIPELINE DRUGS
16 PROBABILITY OF SUCCESS
17 CLINICAL TRIAL LANDSCAPE
18 Sponsors by status
19 Sponsors by phase
21 BIBLIOGRAPHY
23 APPENDIX
LIST OF FIGURES
10 Figure 1: Zika cases timeline
11 Figure 2: Overview of pipeline drugs for Zika virus in the US
11 Figure 3: Pipeline drugs for Zika virus, by company
12 Figure 4: Pipeline drugs for Zika virus, by drug type
12 Figure 5: Pipeline drugs for Zika virus, by classification
16 Figure 6: Probability of success in the antiviral pipeline
17 Figure 7: Clinical trials in Zika virus
17 Figure 8: Top 10 drugs for clinical trials in Zika virus
18 Figure 9: Top 10 companies for clinical trials in Zika virus
18 Figure 10: Zika virus trial locations
19 Figure 11: Zika virus trials status
20 Figure 12: Zika virus trials sponsors, by phase
LIST OF TABLES
13 Table 1: Pipeline drugs for Zika virus in the US